Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:24:35 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:FARO - FARO TECHNOLOGIES INC - http://www.faro.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FARO - Q9.918.62·19.249.918.92+0.472.5128.42,3281,66318.53  19.13  18.3524.80  10.3017:32:51Apr 2515 min RT 2¢

Recent Trades - Last 10 of 1663
Time ETExPriceChangeVolume
17:32:51Q18.920.4731,100
16:20:01Q18.920.47148
16:13:43Q18.920.477
16:01:59Q18.920.47284
16:01:34Q18.920.47452
16:01:32Q18.920.47312
16:00:06Q18.920.47576
16:00:06Q18.920.4714
16:00:06Q18.920.47148
16:00:02Q18.920.47147

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-25 16:05U:FARONews ReleaseFARO to Announce Financial Results for the First Quarter 2024 on May 1, 2024
2024-04-16 02:00U:FARONews ReleaseFaron Confirms Plans for the Coming Months Under New Leadership
2024-03-18 09:00U:FARONews ReleaseInside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML
2024-03-14 03:00U:FARONews ReleaseFaron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab
2024-03-13 03:00U:FARONews ReleaseFaron's Financial Statement Release January 1 to December 31, 2023
2024-03-05 08:00U:FARONews ReleaseFARO Technologies to Webcast 2024 Investor Event on Monday, March 11, 2024
2024-02-27 16:05U:FARONews ReleaseFARO Announces Fourth Quarter and Full Year 2023 Financial Results
2024-02-13 09:17U:FARONews ReleaseFARO to Announce Financial Results for the Fourth Quarter and Year End 2023 on February 28, 2024
2024-01-25 02:00U:FARONews ReleaseDetailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population
2024-01-16 16:05U:FARONews ReleaseFARO Technologies Announces CFO Transition
2024-01-09 02:00U:FARONews ReleaseInside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial
2024-01-03 02:00U:FARONews ReleaseFaron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-29 16:00U:FARONews ReleaseFARO Successfully Completes SOC 2 Type II Audit
2023-12-11 02:00U:FARONews ReleaseInside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting
2023-12-07 02:00U:FARONews ReleaseFaron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine
2023-11-06 02:00U:FARONews ReleaseInsider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS
2023-11-02 09:00U:FARONews ReleaseFaron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting
2023-11-01 16:05U:FARONews ReleaseFARO Announces Third Quarter Financial Results
2023-10-27 02:05U:FARONews ReleaseInside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade Register
2023-10-25 16:10U:FARONews ReleaseFARO to Announce Financial Results for the Third Quarter 2023 on November 2, 2023